This study is designed to evaluate the potential for a PK drug-drug interaction between FV-100 and ritonavir. The study is a single-center, open-label, randomized, 2-way crossover design in healthy volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Subjects will be randomized to one of two treatment sequences: AB or BA.
The evaluation of safety of a single oral dose of FV-100 alone and when combined with a single oral dose of ritonavir
Measuring the Cmax, Tmax and AUC for FV-100 pk profile
Time frame: Two weeks
The evaluation of the pharmacokinetics of FV-100 and CF-1743 following a single oral dose of FV-100 administered alone and with a single oral dose of ritonavir
Measuring the Cmax, Tmax and AUC for FV-100 pk profile when dosed with ritonavir
Time frame: Two weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.